{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:00:22Z","timestamp":1780999222581,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00259-026-07846-x","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:57:19Z","timestamp":1773968239000},"page":"5013-5021","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiation induced lymphopenia during PRRT: Incidence, course, predictive factors, and association with overall survival"],"prefix":"10.1007","volume":"53","author":[{"given":"Gerdi G.","family":"de Harder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayenne H. A. M.","family":"Veerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9233-6616","authenticated-orcid":false,"given":"Milou M -","family":"Steemers - de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5223-9538","authenticated-orcid":false,"given":"Tom T. P.","family":"Seijkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6434-6436","authenticated-orcid":false,"given":"Jos\u00e9","family":"Belderbos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8885-4638","authenticated-orcid":false,"given":"Margot E. T.","family":"Tesselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4910-3794","authenticated-orcid":false,"given":"Else A.","family":"Aalbersberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"2","key":"7846_CR1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2307\/3577549","volume":"123","author":"N Nakamura","year":"1990","unstructured":"Nakamura N, Kusunoki Y, Akiyama M. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. Radiat Res. 1990;123(2):224\u20137.","journal-title":"Radiat Res"},{"key":"7846_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","volume":"123","author":"BP Venkatesulu","year":"2018","unstructured":"Venkatesulu BP, et al. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol. 2018;123:42\u201351.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"7846_CR3","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.ijrobp.2021.07.1695","volume":"111","author":"PJJ Damen","year":"2021","unstructured":"Damen PJJ, et al. The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2021;111(4):936\u201348.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7846_CR4","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/ae0d29","author":"CK S","year":"2025","unstructured":"S CK, et al. Predicting lymphocyte dose and surviving fraction for VMAT and IMPT treatments with a dynamic lymphocyte flow model for locally advanced cervical cancer. Phys Med Biol. 2025. https:\/\/doi.org\/10.1088\/1361-6560\/ae0d29.","journal-title":"Phys Med Biol"},{"issue":"2","key":"7846_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.101038","volume":"8","author":"Y El Houat","year":"2023","unstructured":"El Houat Y, et al. Meta-analysis and critical review: association between radio-induced lymphopenia and overall survival in solid cancers. Adv Radiat Oncol. 2023;8(2):101038.","journal-title":"Adv Radiat Oncol"},{"issue":"11","key":"7846_CR6","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1007\/s00259-006-0172-9","volume":"33","author":"JP Esser","year":"2006","unstructured":"Esser JP, et al. Comparison of [(177)Lu-DOTA(0), Tyr(3)]octreotate and [(177)Lu-DOTA(0), Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging. 2006;33(11):1346\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7846_CR7","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","volume":"38","author":"L Bodei","year":"2011","unstructured":"Bodei L, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"44","key":"7846_CR8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2308511120","volume":"120","author":"R Sender","year":"2023","unstructured":"Sender R, et al. The total mass, number, and distribution of immune cells in the human body. Proc Natl Acad Sci USA. 2023;120(44):e2308511120.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"7846_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/01926230600867743","volume":"34","author":"MF Cesta","year":"2006","unstructured":"Cesta MF. Normal structure, function, and histology of the spleen. Toxicol Pathol. 2006;34(5):455\u201365.","journal-title":"Toxicol Pathol"},{"key":"7846_CR10","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). 2017; Available from: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events."},{"issue":"5","key":"7846_CR11","doi-asserted-by":"publisher","DOI":"10.1148\/ryai.230024","volume":"5","author":"J Wasserthal","year":"2023","unstructured":"Wasserthal J, et al. TotalSegmentator: robust segmentation of 104 anatomic structures in CT images. Radiol Artif Intell. 2023;5(5):e230024.","journal-title":"Radiol Artif Intell"},{"issue":"2","key":"7846_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"9","key":"7846_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/RLU.0000000000005330","volume":"49","author":"M Mileva","year":"2024","unstructured":"Mileva M, et al. 177 Lu-DOTATATE PRRT safety and organ-at-risk dosimetry in patients with gastroenteropancreatic neuroendocrine tumors\u202f: data from the prospective phase 2 LUMEN study. Clin Nucl Med. 2024;49(9):847\u201353.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"7846_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100761","volume":"6","author":"M Alexandru","year":"2021","unstructured":"Alexandru M, et al. Assessing the spleen as an organ at risk in radiation therapy and its relationship with radiation-induced lymphopenia: a retrospective study and literature review. Adv Radiat Oncol. 2021;6(6):100761.","journal-title":"Adv Radiat Oncol"},{"key":"7846_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1201500","volume":"13","author":"H Paganetti","year":"2023","unstructured":"Paganetti H. A review on lymphocyte radiosensitivity and its impact on radiotherapy. Front Oncol. 2023;13:1201500.","journal-title":"Front Oncol"},{"issue":"6","key":"7846_CR16","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","volume":"37","author":"C Hindorf","year":"2010","unstructured":"Hindorf C, et al. EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37(6):1238\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"7846_CR17","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.2967\/jnumed.123.267098","volume":"65","author":"L Steinhelfer","year":"2024","unstructured":"Steinhelfer L, et al. Spleen volume reduction is a reliable and independent biomarker for long-term risk of leukopenia development in peptide receptor radionuclide therapy. J Nucl Med. 2024;65(8):1244\u20139.","journal-title":"J Nucl Med"},{"key":"7846_CR18","doi-asserted-by":"publisher","first-page":"1568243","DOI":"10.3389\/fendo.2025.1568243","volume":"16","author":"R Ferrara","year":"2025","unstructured":"Ferrara R, et al. Predictive factors for persistent thrombocytopenia after peptide receptor radioligand therapy in enteropancreatic neuroendocrine tumors. Front Endocrinol (Lausanne). 2025;16:1568243.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7846_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246193","author":"JY Jin","year":"2021","unstructured":"Jin JY, et al. Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage III NSCLC: a secondary analysis of RTOG0617. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13246193.","journal-title":"Cancers (Basel)"},{"issue":"Suppl 1","key":"7846_CR20","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1530\/eje.0.143s009","volume":"143","author":"SP Oomen","year":"2000","unstructured":"Oomen SP, et al. Somatostatin receptors in the haematopoietic system. Eur J Endocrinol. 2000;143(Suppl 1):S9-14.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"7846_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-015-1841-y","volume":"124","author":"JL Campian","year":"2015","unstructured":"Campian JL, et al. Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas. J Neurooncol. 2015;124(2):307\u201316.","journal-title":"J Neurooncol"},{"key":"7846_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216714","volume":"588","author":"J Kim","year":"2024","unstructured":"Kim J, et al. From lymphopenia to restoration: IL-7 immunotherapy for lymphocyte recovery in glioblastoma. Cancer Lett. 2024;588:216714.","journal-title":"Cancer Lett"},{"issue":"1","key":"7846_CR23","volume":"7","author":"JL Campian","year":"2025","unstructured":"Campian JL, et al. Phase I study of NT-I7, a long-acting interleukin-7, in severe treatment-related lymphopenia following standard radiation and temozolomide for high-grade glioma. Neurooncol Adv. 2025;7(1):vdaf117.","journal-title":"Neurooncol Adv"},{"issue":"5","key":"7846_CR24","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1007\/s00259-022-06094-z","volume":"50","author":"C Veerman","year":"2023","unstructured":"Veerman C, et al. The effect of long-acting somatostatin analogues on the uptake of [(177)Lu]Lu-HA-DOTATATE. Eur J Nucl Med Mol Imaging. 2023;50(5):1434\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7846_CR25","unstructured":"EU Clinical Trials. Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with long-acting Somatostatin Analogues \u2013 ATSA trial. 2024; Available from: https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&EUCT=2023-505884-35-00."},{"key":"7846_CR26","unstructured":"SMPC, Lutathera 370 MBq\/mL solution for infusion. 2018: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lutathera."},{"issue":"1","key":"7846_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","volume":"42","author":"L Bodei","year":"2015","unstructured":"Bodei L, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42(1):5\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07846-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07846-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07846-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:24:58Z","timestamp":1780997098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07846-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7846"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07846-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Institutional Research Board (IRBd2023-008). All patients signed a general consent for the use of their data in retrospective studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}